Novavax: differenze tra le versioni

Versione delle 23:58, 6 dic 2021

Versione delle 00:12, 7 dic 2021

Riga 47:

Nel 2015, Novavax ha ricevuto una sovvenzione di ricerca di 89 milioni di dollari dalla [[Bill and Melinda Gates Foundation]] per sostenere lo sviluppo di un vaccino contro il [[virus respiratorio sinciziale umano]] (hRSV) per i bambini tramite l'[[immunità passiva|immunizzazione materna]].<ref>{{Cite web|title=Gaithersburg Biotech Receives Grant Worth up to $89&nbsp;million|url=http://www.bizjournals.com/washington/blog/2015/09/gaithersburg-biotech-receives-grant-worth-up-to-89.html|url-status=live|archive-url=https://web.archive.org/web/20170401134305/http://www.bizjournals.com/washington/blog/2015/09/gaithersburg-biotech-receives-grant-worth-up-to-89.html|archive-date=1 April 2017|access-date=28 March 2017|website=Bizjournals.com}}</ref><ref>{{Cite web|title=With promising RSV data in hand, Novavax wins $89M Gates grant for PhIII {{!}} FierceBiotech|url=http://www.fiercebiotech.com/r-d/promising-rsv-data-hand-novavax-wins-89m-gates-grant-for-phiii|url-status=live|archive-url=https://web.archive.org/web/20170414010252/http://www.fiercebiotech.com/r-d/promising-rsv-data-hand-novavax-wins-89m-gates-grant-for-phiii|archive-date=14 April 2017|access-date=28 March 2017|website=Fiercebiotech.com|language=en}}</ref><ref>{{Cite news|date=29 September 2016|title=Novavax RSV vaccine found safe for pregnant women, fetus|work=Reuters|url=https://www.reuters.com/article/us-novavax-study-idUSKCN0RT19V20150929|url-status=live|access-date=28 March 2017|archive-url=https://web.archive.org/web/20161007194803/http://www.reuters.com/article/us-novavax-study-idUSKCN0RT19V20150929|archive-date=7 October 2016}}</ref><ref>{{Cite news|last=Herper|first=Matthew|title=Gates Foundation Backs New Shot To Prevent Babies From Dying Of Pneumonia|work=Forbes|url=https://www.forbes.com/sites/matthewherper/2015/09/29/gates-foundation-backs-new-shot-to-prevent-babies-from-dying-of-pneumonia/#1a3b1aea78d4|url-status=live|access-date=28 March 2017|archive-url=https://web.archive.org/web/20160921122505/http://www.forbes.com/sites/matthewherper/2015/09/29/gates-foundation-backs-new-shot-to-prevent-babies-from-dying-of-pneumonia/#1a3b1aea78d4|archive-date=21 September 2016}}</ref>

Nel maggio 2020, Novavax ha ricevuto 384 milioni di dollari dalla [[Coalition for Epidemic Preparedness Innovations]] (CEPI) per finanziare la valutazione in fase iniziale in adulti sani del candidato al [[vaccino COVID-19]] dell'azienda: [[Vaccino anti COVID-19 Novavax| NVX-CoV2373]] e per sviluppare risorse in preparazione alla produzione su larga scala, se il il vaccino ha successo. <ref name="fp">{{Cite news|title=Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work|author=Eric Sagonowsky|url=https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work|work=FiercePharma|date=11 May 2020|access-date=12 May 2020|archive-date=16 May 2020|archive-url=https://web.archive.org/web/20200516215744/https://www.fiercepharma.com/vaccines/novavax-scores-cepi-s-largest-award-up-to-384m-to-support-covid-19-vaccine-work|url-status=live}}</ref> Il CEPI aveva investito, già a marzo, 4 milioni di dollari. <ref name="fp"/>

==Farmaci e vaccini in fase di sviluppo==